The Law Firm of Weiss & Lurie Investigates Ardea Biosciences, Inc.
April 23 2012 - 3:43PM
Business Wire
Weiss & Lurie, a national class action and shareholder
rights law firm with offices in New York City and Los Angeles, is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Ardea Biosciences,
Inc. (NASDAQ: RDEA) arising from its agreement for Ardea to be
acquired by AstraZeneca for $23.00 per share. The transaction is
expected to close during the second or third quarter of 2012,
subject to customary conditions.
Weiss & Lurie is investigating whether Ardea’s Board acted
in the best interests of Ardea shareholders in approving this deal
and whether Ardea shareholders are receiving the highest price for
their shares. Analysts have set the target price for Ardea stock
over $32.00 with a high target set at $41.00 per share.
If you own Ardea shares and would like more information about
your rights as a shareholder or additional information concerning
our investigation, please contact Michael A. Rogovin either by
telephone at (888) 593-4771 or email at info@weisslurie.com.
Weiss & Lurie has litigated hundreds of stockholder class
and derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for defrauded
institutions and individuals and obtained important corporate
governance in these cases. If you have information or would like
legal advice concerning possible corporate wrongdoing (including
insider trading, waste of corporate assets, accounting fraud, or
issuing materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at info@weisslurie.com or fill out the form on our
website, http://www.weisslurie.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar
outcome.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Oct 2023 to Oct 2024